Neutralizing Activity of BNT162b2-Elicited Serum — Preliminary Report

Share this page:

Title

Neutralizing Activity of BNT162b2-Elicited Serum — Preliminary Report

Subject

Description

BNT162b2 is a nucleoside-modified RNA vaccine expressing the full-length prefusion spike glycoprotein (S) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In a randomized, placebo-controlled clinical trial involving approximately 44,000 participants, immunization conferred 95% efficacy against coronavirus disease 2019 (Covid-19).

Date Last Updated (Year-Month-Day)

2021-02-17

Citation

Liu, Yang, Jianying Liu, Hongjie Xia, Xianwen Zhang, Camila R. Fontes-Garfias, Kena A. Swanson, Hui Cai, Ritu Sarkar, Wei Chen, Mark Cutler, David Cooper, Scott C. Weaver, Alexander Muik, Ugur Sahin, Kathrin U. Jansen, Xuping Xie, Philip R. Dormitzer, and Pei-Yong Shi. 2021. "Neutralizing Activity of BNT162b2-Elicited Serum — Preliminary Report." New England Journal of Medicine.

Accessibility

Free online on NEJM.